CELLECTIS SA Announces An Agreement With Shire Pharmaceuticals In The Field Of Gene Activated Proteins

Cellectis S.A. announced today that they entered into an agreement with Shire Pharmaceuticals, by which Cellectis will grant Shire a worldwide non-exclusive commercial license relating to it site-directed genome engineering technologies for creating and developing genetically engineered cells to produce certain gene activated biopharmaceuticals. Financial terms and conditions of the agreement were not disclosed.

Back to news